Anti-CA19-9 Antibody (121SLE)

Datasheet
Specifications
Clonality: Monoclonal
Host: Mouse
Reactivity: Human
Applications: FC, IF, IHC
Additional Information
Synonyms: CA19.9, Ovarian tumor antigen, Pancreatic tumor antigen, Sialyl Lewisa

Immunogen

Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient

Application

FC: 0.5-1 ug/1X106 cells, IF: 0.5-1 ug/ml, IHC: 0.5-1 ug/ml

Background

CA19-9, a carbohydrate epitope expressed on a high MW (>400 kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.

  • Catalog Number
    A1451-100-BV
  • Supplier
    BioVision
  • Size
  • Shipping
    Blue Ice
  • Price
  • 492,00 €
Add to Cart
you need any help?

Please contact:

Dr. Monika Haas

Tel. +49 (0) 6221 71415 16 info@biocat.com